Ambros Therapeutics, Inc.

Based in the US, Ambros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for complex regional pain syndrome type 1 (CRPS-1). Ambros Therapeutics, Inc. is dedicated to advancing treatments for complex regional pain syndrome type 1.

Founded in 2024 in Irvine, US, the company has raised USD 125. 00 mn in its Series A funding round, which closed in December 2025, led by investors including RA Capital Management and Enavate Sciences. The company has secured a total of USD 125. 00 mn to date.

The founder's previous history is not specified, and there are no known subsidiaries or significant pivots in business strategy. Ambros Therapeutics specializes in the development of innovative therapeutics targeting complex regional pain syndrome type 1 (CRPS-1), a rare and debilitating metabolic bone disease characterized by severe pain and functional impairments following trauma. The company's primary product candidate, neridronate, is a third-generation bisphosphonate specifically designed to provide a disease-modifying therapy for patients suffering from warm CRPS-1. Neridronate operates by utilizing its unique binding characteristics to enhance safety and efficacy compared to traditional bisphosphonates.

Currently, there are no FDA-approved treatments for CRPS-1, creating a critical demand for effective solutions among this patient population, which is estimated to be between 50,000 to 70,000 individuals in the U. S. and EU. Ambros Therapeutics is focused on clinical trials within the United States and European markets to bring neridronate to patients in need.

Ambros Therapeutics is currently in the clinical stage, primarily reliant on funding mechanisms such as venture capital and private investments to support the development of neridronate through its Phase 3 pivotal trial, known as CRPS-RISE. Revenue generation will be contingent upon successful clinical outcomes and subsequent regulatory approvals, enabling the company to transition to sales and marketing of neridronate. As the primary product candidate, neridronate is anticipated to be marketed directly to healthcare providers and institutions specializing in pain management and rehabilitation for CRPS-1 patients. The structure of future transactions is expected to be B2B, with potential distribution partnerships or collaborations with healthcare networks.

Pricing strategies for neridronate will be determined post-approval, aligning with industry standards for innovative treatments in specialty care. Ambros Therapeutics aims to utilize the USD 125. 00 mn raised in its Series A funding to advance the pivotal Phase 3 clinical trial of neridronate for CRPS-1, along with carrying out necessary regulatory work and pre-commercial initiatives. The company is focused on expediting the development of new therapeutics and plans to expand its clinical trials into additional markets in Europe by 2026.